Baxter International Inc. closed 24.01% short of its 52-week high of $44.01, which the company reached on March 8th.

Baxter International shares surged Thursday after the medical device maker's fourth-quarter results topped estimates.

Barclays reinstated coverage of Baxter (BAX) with an Overweight rating and $39 price target The firm updated its sales projections to reflect ...

Reports Q4 revenue $2.75B, consensus $2.67B. “Our 2024 performance and related strategic milestones reflect Baxter’s (BAX) growing momentum in ...

Baxter International Inc. ( NYSE: BAX) Q4 2024 Earnings Conference Call February 20, 2025 8:30 AM ET Clare Trachtman - SVP and Chief IRO Brent Shafer - Chairman, and Interim CEO Heather Knight - COO ...

Following the completion of a massive restructuring plan, the medical equipment giant projects 4% to 5% sales growth this ...

The stock's fall snapped a three-day winning streak.

Q4 2024 Management View Interim CEO Brent Shafer highlighted the completion of the Vantive sale as a significant milestone in Baxter's transformation strategy and noted the company's focus on ...

As of 2:35:06 PM EST. Market Open. DEERFIELD, Ill., February 18, 2025--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the TD Cowen 45th Annual Health Care ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

DEERFIELD, Ill., February 13, 2025--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Citi - 2025 Medtech & Life Sciences Access Day on Thursday, February 27, 2025.

Baxter International Inc. (NYSE:BAX) is expected to report an EPS of $0.81 and revenue of approximately $2.67 billion for its ...